4.7 Article

Operationalizing protocol differences for EADC-ADNI manual hippocampal segmentation

Journal

ALZHEIMERS & DEMENTIA
Volume 11, Issue 2, Pages 184-194

Publisher

WILEY
DOI: 10.1016/j.jalz.2013.03.001

Keywords

Hippocampus; Hippocampal atrophy; Hippocampal volumetry; Manual segmentation protocol; Harmonization; Anatomic landmark; Alzheimer's disease; Manual tracing; Medial temporal lobes; Atrophy; Degeneration; Magnetic resonance; Neuroimaging; Alzheimer's Disease Neuroimaging Initiative; Standard operating procedures

Funding

  1. Wyeth, part of the Pfizer group
  2. Lilly
  3. Alzheimer's Association [IIRG -10-174022]
  4. ADNI (National Institutes of Health) [U01 AG024904]
  5. National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering
  6. Abbott
  7. Alzheimer's Association
  8. Alzheimer's Drug Discovery Foundation
  9. Amorfix Life Sciences Ltd.
  10. AstraZeneca
  11. Bayer Health Care
  12. BioClinica, Inc.
  13. Biogen Idec Inc.
  14. Bristol-Myers Squibb Company
  15. Eisai Inc.
  16. Elan Pharmaceuticals Inc.
  17. Eli Lilly and Company
  18. F. Hoffmann-La Roche Ltd, company Genentech, Inc.
  19. GE Healthcare
  20. Innogenetics, N.V.
  21. IXICO Ltd.
  22. Janssen Alzheimer Immunotherapy Research & Development, LLC
  23. Johnson & Johnson Pharmaceutical Research & Development LLC
  24. Medpace, Inc.
  25. Merck Co., Inc.
  26. Meso Scale Diagnostics, LLC
  27. Novartis Pharmaceuticals Corporation
  28. Pfizer Inc.
  29. Servier
  30. Synarc Inc.
  31. Takeda Pharmaceutical Company
  32. Canadian Institutes of Health Research
  33. National Institutes of Health [P30 AG010129, K01 AG030514]
  34. Ministere du Developpement Economique, de l'Innovation et de l'Exportation du Quebec

Ask authors/readers for more resources

Background: Hippocampal volumetry on magnetic resonance imaging is recognized as an Alzheimer's disease (AD) biomarker, and manual segmentation is the gold standard for measurement. However, a standard procedure is lacking. We operationalize and quantitate landmark differences to help a Delphi panel converge on a set of landmarks. Methods: One hundred percent of anatomic landmark variability across 12 different protocols for manual segmentation was reduced into four segmentation units (the minimum hippocampus, the alveus/fimbria, the tail, and the subiculum), which were segmented on magnetic resonance images by expert raters to estimate reliability and AD-related atrophy. Results: Intra- and interrater reliability were more than 0.96 and 0.92, respectively, except for the alveus/fimbria, which were 0.86 and 0.77, respectively. Of all AD-related atrophy, the minimum hippocampus contributed to 67%; tail, 24%; alveus/fimbria, 4%; and the subiculum, 5%. Conclusions: Anatomic landmark variability in available protocols can be reduced to four discrete and measurable segmentation units. Their quantitative assessment will help a Delphi panel to define a set of landmarks for a harmonized protocol. (C) 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available